Results 21 to 30 of about 7,117 (221)

Distinct Effects of Ibrutinib and Acalabrutinib on Mouse Atrial and Sinoatrial Node Electrophysiology and Arrhythmogenesis

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2021
Background Ibrutinib and acalabrutinib are Bruton tyrosine kinase inhibitors used in the treatment of B‐cell lymphoproliferative disorders. Ibrutinib is associated with new‐onset atrial fibrillation.
Jari M. Tuomi, Loryn J. Bohne, Tristan W. Dorey, Hailey J. Jansen, Yingjie Liu, Douglas L. Jones, Robert A. Rose   +6 more
doaj   +1 more source

Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia

Haematologica, 2021
B-cell receptor signalling inhibition by targeting Bruton tyrosine kinase (BTK) is effective in treating chronic lymphocytic leukemia (CLL). The BTK inhibitor ibrutinib may be intolerable for some patients.
Kerry A. Rogers, Philip A. Thompson, John N. Allan, Morton Coleman, Jeff P. Sharman, Bruce D. Cheson, Daniel Jones, Raquel Izumi, Melanie M. Frigault, Cheng Quah, Rakesh K. Raman, Priti Patel, Min Hui Wang, Thomas J. Kipps   +13 more
doaj   +1 more source

Preclinical Evaluation of the Novel BTK Inhibitor Acalabrutinib in Canine Models of B-Cell Non-Hodgkin Lymphoma. [PDF]

PLoS ONE, 2016
Acalabrutinib (ACP-196) is a second-generation inhibitor of Bruton agammaglobulinemia tyrosine kinase (BTK) with increased target selectivity and potency compared to ibrutinib.
Bonnie K Harrington, Heather L Gardner, Raquel Izumi, Ahmed Hamdy, Wayne Rothbaum, Kevin R Coombes, Todd Covey, Allard Kaptein, Michael Gulrajani, Bart Van Lith, Cecile Krejsa, Christopher C Coss, Duncan S Russell, Xiaoli Zhang, Bridget K Urie, Cheryl A London, John C Byrd, Amy J Johnson, William C Kisseberth   +18 more
doaj   +1 more source

Data Mining for Adverse Events Signals of Acalabrutinib Based on FAERS Database

Zhongliu Fangzhi Yanjiu, 2022
Objective To explore the potential adverse reactions of acalabrutinib by mining and analyzing the pharmacovigilance signal of acalabrutinib, to provide a reference for clinically safe and rational drug use.
LIANG Cuilyu, ZHANG Yin, CHEN Qiying
doaj   +1 more source

Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN.

Blood
Key Points • First-line acalabrutinib-obinutuzumab resulted in significantly higher PFS and OS than chemoimmunotherapy regardless of high-risk features.• Acalabrutinib-obinutuzumab resulted in improved PFS rates vs acalabrutinib monotherapy in a post hoc
Sharman JP, Egyed M, Jurczak W, Skarbnik A, Patel K, Flinn IW, Kamdar M, Munir T, Walewska R, Hughes M, Fogliatto LM, Herishanu Y, Banerji V, Follows G, Walker P, Ghia P, Janssens A, Byrd JC, Ferrant E, Ferrajoli A, Wierda WG, Wachira CW, Suterwala BT, Miranda P, Munugalavadla V, Wun CC, Woyach JA.   +26 more
europepmc   +2 more sources

Triplet regimens for frontline treatment of CLL-Great company or just a crowd? [PDF]

Hemasphere
Abstract Standard frontline treatment of chronic lymphocytic leukemia (CLL) is with fixed‐duration venetoclax‐based doublets or indefinite covalent Bruton tyrosine kinase inhibitor (BTKI). Although these approaches achieve excellent results, venetoclax doublets have diminished efficacy in high‐risk biological subgroups, and indefinite covalent Bruton ...
McKeague S, Seymour JF.
europepmc   +2 more sources

Bruton Tyrosine Kinase Inhibitors in Mantle Cell Lymphoma: What Are the Current Options? [PDF]

Eur J Haematol
ABSTRACT Mantle Cell Lymphoma (MCL) is an aggressive B‐cell non‐Hodgkin lymphoma characterized by the hallmark t(11;14)(q13;q32) translocation, resulting in cyclin D1 overexpression. Predominantly affecting elderly males, MCL exhibits marked clinical and biological heterogeneity, ranging from indolent SOX11‐negative variants to highly proliferative ...
Caserta S, Martino EA, Vigna E, Bruzzese A, Amodio N, Lucia E, Olivito V, Labanca C, Mendicino F, Morabito F, Gentile M.   +10 more
europepmc   +2 more sources

Cirmtuzumab inhibits Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia treated with ibrutinib. [PDF]

, 2016
Signaling via the B cell receptor (BCR) plays an important role in the pathogenesis and progression of chronic lymphocytic leukemia (CLL). This is underscored by the clinical effectiveness of ibrutinib, an inhibitor of Bruton's tyrosine kinase (BTK) that
Chen, L, Chen, Y, Choi, MY, Cui, B, Kipps, TJ, Rassenti, LZ, Widhopf Ii, GF, Wu, Christina, Yu, J, Zhang, L   +9 more
core   +1 more source

Acalabrutinib‐related second primary malignancies and nonmelanoma skin cancers in patients with chronic lymphocytic leukaemia (CLL): A systematic review and meta‐analysis of randomised controlled trials (RCTs)

eJHaem, 2021
Acalabrutinib is a second generation Bruton's tyrosine kinase inhibitor and was recently approved in the treatment of chronic lymphocytic leukaemia. We undertook a systematic review and meta‐analysis of randomised controlled trials to determine the risks
Thura W. Htut, Myat M. Han, Kyaw Z. Thein   +2 more
doaj   +1 more source

Targeting Brutons Tyrosine Kinase in Chronic Lymphocytic Leukemia at the Crossroad between Intrinsic and Extrinsic Pro-survival Signals [PDF]

, 2016
Chemo immunotherapies for chronic lymphocytic leukemia (CLL) showed a positive impact on clinical outcome, but many patients relapsed or become refractory to the available treatments.
Facco, Monica, Frezzato, Federica, Martini, Veronica, Semenzato, Gianpietro, Severin, Filippo, Trentin, Livio, Trimarco, Valentina, Visentin, Andrea   +7 more
core   +1 more source